MEDICINES CO /DE filed this form 10-Q on 15 May 2002
<PAGE> 14 11. PUBLICITY AND ANNOUNCEMENTS. 11.1. Subject to Article 11.2 no press release, announcement or any other communication to any Third Party concerning the transaction contemplated by this Agreement, the financial terms of this Agreement, the subject matter of this Agreement or any ancillary matters shall be made or permitted or authorized to be made by either Party without the prior written approval of the other, such approval not to be unreasonably withheld or delayed and such approval to be given by an authorized representative of the Party in question. Notwithstanding the above, TMC may make the press announcement set forth in Schedule 4 at the Effective Date or in immediate connection therewith. 11.2. Either Party may make an announcement concerning the transaction contemplated by this Agreement or any ancillary matter if required by law, existing contractual obligations or any securities exchange or Regulatory Authority or governmental body to which either Party is subject or submits, wherever situated, provided that the Party required to make such announcement notifies the other Party of the details of the announcement prior to making such announcement and in sufficient time for the other Party to consider and comment on the announcement, and takes advantage of all provisions to keep confidential as many terms of the Agreement as possible. 12. NO GRANT OF RIGHTS Nothing in this Agreement shall be interpreted expressly or implied as granting either Party any licence or other rights, except as expressly set out in this Agreement. 13. DISCLAIMER 13.1. Any Samples so furnished by ASTRAZENECA to TMC hereunder are to be treated by TMC as potentially hazardous in handling and use and ASTRAZENECA gives no warranty or representation regarding the safety or efficacy of the Compound.